Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum

Brownlee, 2020, Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic, Neurology, 10.1212/WNL.0000000000009507

Giovannoni, 2020, The COVID-19 pandemic and the use of MS disease-modifying therapies, Mult Scler Relat Disord

Montalban, 2017, Ocrelizumab versus placebo in primary progressive multiple sclerosis, N Engl J Med, 376, 209, 10.1056/NEJMoa1606468

Zhu, 2020, Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression, Am J Transplant, 10.1111/ajt.15869

Monti, 2020, Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies, Ann Rheum Dis, 10.1136/annrheumdis-2020-217424

Huang, 2020, COVID-19 in post-transplantation patients – report of two cases, Am J Transplant, 10.1111/ajt.15896

Zhang, 2020, Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China, Ann Oncol

https://www.arsep.org/fr/actualites/coronavirus_covid_19.html and https://sfsep.org/conseils-a-propos-du-covid-19-pour-les-personnes-atteintes-de-sep/.